1IBHub — The targeted B2B partnering platform for pharmaceutical in-licensing, out-licensing and cross-border portfolio growth.

1IBHub

News & Industry Deal Insights

Structured breakdowns of pharmaceutical business development, licensing and M&A transactions — written for portfolio and BD decision makers.

Pharma BD Focus: RNAi Obesity Alliances, Protein-Elimination Drugs and Biotech Reverse Mergers

Roche (SIX: ROG) and Rona Therapeutics feature in a reported $1 billion alliance for an RNA interference (RNAi) obesity drug. Pfizer (NYSE: PFE) has signed a collaboration with Enodia Therapeutics, reported at more than $500 million, to develop small molecules that eliminate disease-causing proteins where they are made. Neither selected item's title or snippet specifies clinical stage, named molecular targets or detailed payment schedules.

  • Roche Rona RNAi obesity alliance
  • Pfizer Enodia Therapeutics collaboration
  • small-molecule protein elimination
  • Paragon biotech reverse merger
  • pharma business development
Read Full Article

Strategic Biopharma Transactions: PD-1xVEGF Bispecific Alliances, Preclinical KRAS Acquisitions, and Next-Gen Incretin Out-Licensing

Recent biopharma dealmaking reflects concentrated corporate capital deployment toward immuno-oncology combination therapies, next-generation metabolic dual-agonists, and precision small-molecule oncology targets. Sanofi, AstraZeneca, Novo Nordisk and Merck have committed over $15 billion in aggregate milestone capital.

  • Biotech M&A
  • PD-1xVEGF Bispecific
  • KRAS G12D Inhibitor
  • GLP-1 Licensing
  • Pharma Business Development
Read Full Article
Weekly Digest
Subscribe to the 1IBHub BD & M&A Digest
Inscribe to stay updated on the latest BD and M&A News in the pharmaceutical industry (weekly digest sent via email).

Stay Connected on LinkedIn

Follow 1IBHub on LinkedIn for latest job offerings, news, and deal analysis in pharmaceutical business development.

Follow 1IBHub on LinkedIn

Strategic Biopharma Transactions: Bispecific Antibodies, Targeted Radioligands, and Genomic RNA Platforms

Recent biopharma dealmaking highlights continuous capital allocation toward clinically validated bispecific antibodies, targeted radioligand therapeutics, and novel non-coding RNA (lncRNA) drug discovery engines. Multi-billion dollar transaction structures reflect Big Pharma's willingness to commit substantial upfront capital to secure ex-China global commercialization rights, particularly in oncology and auto-immunity.

  • M&A
  • Licensing
  • Bispecifics
  • Radiopharmaceuticals
  • lncRNA
Read Full Article

Strategic Biopharma Transactions: Bankruptcy Asset Auctions, GI-Restricted Kinase Mergers, and Oral Immunology Capital

Recent biopharma dealmaking reflects a distinct shift toward capital efficiency, valuation discipline, and specialized modality consolidation. Transactions were anchored by Section 363 bankruptcy asset auctions, corporate reverse mergers paired with PIPE financing, oral immunology alternatives, and synthetic royalty monetization.

  • M&A
  • Licensing
  • Bankruptcy Auctions
  • Immunology
  • ADCs
Read Full Article

Stay Connected on LinkedIn

Follow 1IBHub on LinkedIn for latest job offerings, news, and deal analysis in pharmaceutical business development.

Follow 1IBHub on LinkedIn